What CTX Life Sciences does

CTX Life Sciences (legal entity CTX Lifesciences Pvt. Ltd.) is an India-based, privately held Active Pharmaceutical Ingredient (API) and intermediate manufacturer founded in 2004 in Surat, Gujarat, and operating as the pharmaceutical arm of the Colourtex Group (a diversified dyes, textiles and masterbatches conglomerate with $600M+ annual sales founded in 1967). The company runs a 38-acre cGMP-compliant manufacturing campus in Sachin GIDC, Surat, comprising five production blocks with a collective reactor volume exceeding 1,000 KL, supported by kilo labs, a pilot plant, advanced analytical instrumentation (UHPLC, GC-MS, XRD, ICP OES, DSC, Karl Fischer), and full environmental infrastructure (ETP, MEE, ATFD, 5,850 TR cooling, 4,250 KVA power backup). Its R&D arm is a 12,000 sq ft DSIR-approved laboratory staffed by 77+ scientists covering process and analytical development for 30+ reaction types including oxidative chlorination, catalytic reduction, enzymatic reactions, Vilsmeier Haack and asymmetric reductions.

The company's product portfolio spans 40+ commercial APIs across anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, diuretic, CNS and cardiovascular therapeutic categories, 20+ pharmaceutical intermediates and four APIs in development (Brivaracetam, Dabigatran Etexilate Mesylate, Edoxaban Tosylate, Mirogabalin Besylate). It serves 800+ customers in 87+ countries via direct B2B export, backed by DMF/CEP filings across US, European, Brazilian, Korean, Japanese, Canadian, Mexican and Russian health authorities, with USFDA inspections completed six times (most recently 2022) and EDQM inspections four times. In parallel, CTX offers CDMO services providing end-to-end process development, scale-up and commercial manufacturing under cGMP, leveraging vertical integration from Key Starting Materials through intermediates to finished APIs. Revenue is generated through transaction-fee API sales, CDMO contracts and intermediate/KSM supply; pricing is not publicly disclosed and customer inquiries are routed through [email protected].

Name

CTX Life Sciences

Legal name

CTX Lifesciences Pvt. Ltd.

Website

https://ctxls.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

CTX Life Sciences is a Surat, India-based, privately held API and intermediate manufacturer operating a USFDA- and EU GMP-inspected facility, supplying 40+ commercial APIs and 20+ intermediates to 800+ pharmaceutical customers across 87+ countries under its parent Colourtex Group.

Ownership category

akta.pro rank

Product category

API Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• API manufacturing
• Pharmaceutical intermediates
• Contract development manufacturing
• CGMP API supply
• Regulatory DMF filings

Headquarters

HQ city

Surat

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. API Sales: Sale of Active Pharmaceutical Ingredients to pharmaceutical companies worldwide with regulatory filings (DMF, CEP) across multiple markets. 40+ commercial APIs covering anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, diuretic segments.
2. Contract Development and Manufacturing (CDMO): End-to-end development and manufacturing services for pharmaceutical companies including process development, optimization, scale-up and commercial production under cGMP conditions.
3. Intermediates and KSM Sales: Manufacturing and supply of pharmaceutical intermediates and Key Starting Materials to pharmaceutical companies. Backward integrated processes offering better control over quality, cost and supply consistency.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

CTX Lifesciences is a vertically integrated pharmaceutical manufacturer that produces 40+ commercial Active Pharmaceutical Ingredients (APIs), 20+ pharmaceutical intermediates, and provides Contract Development and Manufacturing Organization (CDMO) services for global pharmaceutical companies. Manufacturing is conducted under cGMP conditions with regulatory filings (USDMF, CEP, EDMF, KDMF, ANVISA, COFEPRIS, JDMF, NMPA, MOH Russia) supporting exports to 87+ countries. Therapeutic segments covered include anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, and diuretic categories.

Product overview

CTX Lifesciences is a vertically integrated Active Pharmaceutical Ingredient (API) and intermediate manufacturer offering a comprehensive portfolio of 40+ commercial APIs across therapeutic categories including anti-hypertensives, anti-diabetics, anti-coagulants, anti-convulsants, anti-psychotics, and diuretics. The company also develops 4 additional APIs and manufactures 20+ pharmaceutical intermediates. CTX provides Contract Development and Manufacturing Organization (CDMO) services with vertical integration from Key Starting Materials (KSM) to intermediates to finished APIs. All products are manufactured under cGMP conditions with regulatory filings including USDMF, CEP, EDMF, NMPA, KFDA, MOH Russia, ANVISA, and other international drug authorities.

Differentiator

Problem solved

Functional benefit

Products and services

• Commercial APIs A portfolio of 40+ commercial Active Pharmaceutical Ingredients (APIs) sold to pharmaceutical companies worldwide with regulatory filings (USDMF, CEP, KDMF, ANVISA, MOH Russia, COFEPRIS, JDMF, NMPA). Includes products such as Acetazolamide, Alogliptin Benzoate, Apixaban, Azilsartan Medoxomil Potassium, Dapagliflozin Propanediol Monohydrate, Empagliflozin, Linagliptin, Metoprolol Succinate, Pregabalin, Rosuvastatin Calcium, Ticagrelor, and Vildagliptin across therapeutic segments.
• Pharmaceutical Intermediates 20+ pharmaceutical intermediates including 2-Acetylamino-5-mercapto-1,3,4-thiadiazole and other specialty intermediates for APIs such as Acetazolamide, Alogliptin Benzoate, Apixaban, Azilsartan Medoxomil Potassium, Carvedilol, Celecoxib, Chlorthalidone, Dabigatran Etexilate Mesylate, Deferasirox, Eslicarbazepine Acetate, Lamotrigine, Linagliptin, Losartan Potassium, Olmesartan Medoxomil, Rosuvastatin Calcium, Saxagliptin, Sevelamer HCl, and Vildagliptin.
• Contract Development and Manufacturing Organization (CDMO) Services End-to-end contract development and manufacturing services for pharmaceutical companies, including process development, optimization, scale-up and commercial production under cGMP conditions. Includes vertical integration of intermediates and Key Starting Materials (KSM), with state-of-the-art facilities and experienced team supporting project timelines, budget adherence, and attention to quality and safety.

Quantifiable outcome

• Successfully passed 6 USFDA inspections and 4 EDQM inspections demonstrating consistent regulatory compliance
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Colourtex GroupcoreOthersParent company privately owned Colourtex Industries Pvt Ltd founded by Jayantibhai Jariwala in 1967, worth US$ 600 million group. Leading dyestuff manufacturer with 750+ types of dyes and performance chemicals. Provides chemical manufacturing expertise and environmental infrastructure including ETP, MEE, ATFD, power generation, and water treatment facilities. Group also has interests in Textiles and Masterbatches.
• NGOs, Self-Help Groups, Government Bodies, Social EnterprisesminorOthersCSR collaborations for social responsibility initiatives focusing on education, health and wellness, sanitation, environment, and sustainable holistic development in marginalized and economically disadvantaged sections of society.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Divis Laboratories: Indian-based API manufacturer and CDMO with strong complex chemistry capabilities, USFDA-inspected facilities, and a comparable focus on regulated markets — a direct competitor for generic API and contract manufacturing contracts.
• Laurus Labs: Vertically integrated Indian API and CDMO with KSM-to-API integration and strong regulatory filings, competing head-to-head with CTX in generic APIs and emerging CDMO opportunities.
• Aurobindo Pharma: One of India's largest generic API and finished-dose manufacturers with extensive USFDA-inspected facilities and similar therapeutic coverage (cardiovascular, anti-diabetic, CNS) — overlapping customer base and product portfolio.
• Neuland Laboratories: Indian API manufacturer and CDMO focused on complex generics and peptide APIs, with USFDA-inspected facilities and similar product mix to CTX in cardiovascular and CNS therapeutic areas.
• Jubilant Pharmova: Indian pharmaceutical company with significant API manufacturing and CDMO services, including complex chemistry and injectable capabilities, competing for similar CDMO contracts in regulated markets.
• Granules India: Indian API and finished-dose manufacturer with vertically integrated paracetamol, metformin, and other high-volume API capabilities, overlapping with CTX in commodity generic APIs.
• Shilpa Medicare: Indian API and formulation manufacturer with oncology and complex generic focus, sharing the CDMO and regulated API market with CTX.
• Piramal Pharma Solutions: Major Indian CDMO offering API, peptide, and sterile fill-finish services; competes with CTX for innovator pharma contract manufacturing opportunities, with a broader capability set including biologics.
• Sai Life Sciences: Indian CDMO focused on small molecule API development and manufacturing, with strong process R&D capabilities — directly comparable in target customer (innovator pharma) and service offering.

Regional players

• Aarti Drugs: Indian API manufacturer with similar therapeutic area coverage (anti-diabetic, cardiovascular) and export focus, competing with CTX primarily in semi-regulated and emerging markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ctx-lifesciences

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CTX Life Sciences